Sonoma Biotherapeutics logo

Sonoma Biotherapeutics Funding & Investors

South San Francisco, CA

Sonoma Biotherapeutics is a company invloved the development of adoptive Treg therapies cell for autoimmune and degenerative diseases. Using next generation genome editing and target-specific cell therapy, Sonoma is focused on developing its best-in-class platform across the entire spectrum of Treg cell therapeutic capabilities. Founded by pioneers in Treg biology and cell therapy, the company brings together leading expertise and proprietary methodologies for the discovery and development of disease modifying and curative therapies.

sonomabio.com

Total Amount Raised: $365,000,000

Sonoma Biotherapeutics Funding Rounds

  • Corporate Round

    $30,000,000

    Corporate Round Investors

    Regeneron Pharmaceuticals
  • Series B

    $265,000,000

    Series B Investors

    Ally Bridge Group
    Fidelity
    NS Investment
    JDRF T1D Fund
    Lilly Asia Ventures
    ArrowMark Colorado Holdings
    8VC
    Vertex Ventures HC
    Casdin Capital
    GV
    Avidity Partners
    Lifeforce Capital
    Arch Venture Partners
    Henderson Global Investors
    Alexandria Venture Investments
    Mirae Asset
    Deep Track Capital
    OUP (Osage University Partners)
    Frazier Management
    Octagon Capital Advisors
  • Series A

    $30,000,000

    Series A Investors

    Arch Venture Partners
    8VC
    Lilly Asia Ventures
    Lyell Immunopharma
    JDRF T1D Fund
    Alexandria Venture Investments
    Lifeforce Capital
    Octagon Capital Advisors
  • Series A

    $40,000,000

    Series A Investors

    Lyell Immunopharma
    8VC
    Milky Way Ventures
    Arch Venture Partners
Funding info provided by Diffbot.